Jefferies Group Weighs in on Aileron Therapeutics, Inc.’s Q1 2018 Earnings (ALRN)

Aileron Therapeutics, Inc. (NASDAQ:ALRN) – Analysts at Jefferies Group issued their Q1 2018 EPS estimates for shares of Aileron Therapeutics in a report released on Thursday. Jefferies Group analyst E. Yang expects that the company will post earnings per share of ($0.49) for the quarter. Jefferies Group currently has a “Buy” rating and a $20.00 target price on the stock. Jefferies Group also issued estimates for Aileron Therapeutics’ Q2 2018 earnings at ($0.57) EPS, Q3 2018 earnings at ($0.61) EPS and Q4 2018 earnings at ($0.69) EPS.

ALRN has been the topic of several other reports. Canaccord Genuity started coverage on shares of Aileron Therapeutics in a research report on Monday, July 24th. They set a “buy” rating and a $19.00 price objective on the stock. William Blair began coverage on shares of Aileron Therapeutics in a research note on Monday, July 24th. They issued an “outperform” rating for the company. Finally, Bank of America Corporation began coverage on shares of Aileron Therapeutics in a research note on Monday, July 24th. They issued a “buy” rating and a $19.00 target price for the company.

TRADEMARK VIOLATION NOTICE: “Jefferies Group Weighs in on Aileron Therapeutics, Inc.’s Q1 2018 Earnings (ALRN)” was reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.thestockobserver.com/2017/11/14/jefferies-group-weighs-in-on-aileron-therapeutics-inc-s-q1-2018-earnings-alrn.html.

Aileron Therapeutics (NASDAQ ALRN) opened at $11.78 on Monday. Aileron Therapeutics has a 52-week low of $9.58 and a 52-week high of $15.48.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. California State Teachers Retirement System acquired a new stake in shares of Aileron Therapeutics in the third quarter valued at about $110,000. Vanguard Group Inc. acquired a new stake in shares of Aileron Therapeutics in the second quarter valued at about $111,000. Tudor Investment Corp ET AL acquired a new stake in shares of Aileron Therapeutics in the second quarter valued at about $112,000. Bank of New York Mellon Corp acquired a new position in Aileron Therapeutics during the third quarter worth about $135,000. Finally, Schwab Charles Investment Management Inc. acquired a new position in Aileron Therapeutics during the third quarter worth about $165,000. Hedge funds and other institutional investors own 12.39% of the company’s stock.

About Aileron Therapeutics

Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.

Earnings History and Estimates for Aileron Therapeutics (NASDAQ:ALRN)

Receive News & Ratings for Aileron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply